Shares of AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) were up 2.8% during trading on Wednesday . The company traded as high as $3.71 and last traded at $3.66, with a volume of 180,633 shares changing hands. The stock had previously closed at $3.56.

A number of analysts have recently commented on ACRX shares. Janney Montgomery Scott started coverage on shares of AcelRx Pharmaceuticals in a report on Thursday, April 14th. They set a “neutral” rating on the stock. HC Wainwright restated a “buy” rating and set a $7.00 target price (down previously from $9.00) on shares of AcelRx Pharmaceuticals in a report on Tuesday, May 3rd. Cowen and Company restated a “hold” rating on shares of AcelRx Pharmaceuticals in a report on Monday, May 2nd. Seaport Global Securities upgraded shares of AcelRx Pharmaceuticals from an “accumulate” rating to a “buy” rating in a report on Friday, May 6th. Finally, Jefferies Group restated a “buy” rating on shares of AcelRx Pharmaceuticals in a report on Friday, June 10th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $7.63.

The stock has a 50-day moving average price of $3.08 and a 200 day moving average price of $3.34. The stock’s market cap is $169.01 million.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last released its earnings results on Thursday, July 28th. The specialty pharmaceutical company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by $0.02. The business earned $4.53 million during the quarter, compared to analyst estimates of $2.17 million. On average, equities analysts expect that AcelRx Pharmaceuticals Inc. will post ($0.90) earnings per share for the current year.

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.